ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study
Open Access
- 4 May 2011
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 34 (5) , 489-494
- https://doi.org/10.1007/s13402-011-0045-5
Abstract
Background Expression of estrogen receptor alpha (ERα) is predictive for endocrine therapy response and an important prognostic factor in breast cancer. Overexpression of ERα can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated with a significantly longer survival for ER-positive women treated with adjuvant tamoxifen monotherapy, which was however questioned by subsequent studies. Methods This study aimed to reanalyze the frequency of ESR1 amplification by multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridisation (FISH), and to assess clinicopathologic correlations. MLPA was performed in a group of 135 breast cancer patients, and gains/amplifications were subjected to FISH. Results True ESR1 amplification by MLPA was rare (2%) and only 6% more patients showed a modest gain of ESR1. All MLPA-detected ESR1 amplifications and nearly all ESR1 gains were also FISH amplified and gained, but not all FISH amplifications/gains were MLPA amplified/gained, leading to an overall concordance of only 60% between both techniques. All 3 MLPA and FISH ESR1 amplified cases had high ERα expression, but there was no obvious correlation between ESR1 gain and ER status by IHC. ESR1 gains/amplifications were not associated with HER2 gain/amplification, but seemed to be associated with older age. Surprisingly, ESR1 gain/amplification was not associated with low grade as reported previously, but correlated with high grade and high proliferation. Furthermore, ESR1 gain/amplification by MLPA was not associated with nodal status or tumor size (pT status). Conclusions ESR1 amplification as detected by MLPA is rare in breast cancer, and seems to be associated with high ERα expression, high age, high grade and high proliferation. This study confirms previous studies that showed differences in the ESR1 amplification frequencies detected by different techniques.Keywords
This publication has 25 references indexed in Scilit:
- Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancerBreast Cancer Research and Treatment, 2010
- Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancerLaboratory Investigation, 2010
- Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationBreast Cancer Research and Treatment, 2009
- HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissectionBMC Cancer, 2009
- ESR1 gene amplification in breast cancer: a common phenomenon?Nature Genetics, 2008
- Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”Nature Genetics, 2008
- ESR1 gene amplification in breast cancer: a common phenomenon?Nature Genetics, 2008
- ESR1 gene amplification in breast cancer: a common phenomenon?Nature Genetics, 2008
- ESR1 gene amplification in breast cancer: a common phenomenon?Nature Genetics, 2008
- Conflicting evidence on the frequency of ESR1 amplification in breast cancerNature Genetics, 2008